跳至主要内容
临床试验/NCT00289614
NCT00289614已完成4 期

Patients With Renal Impairment and Diabetes Undergoing Computed Tomography

Bracco Diagnostics, Inc2 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2006年1月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
350
试验地点
2
主要终点
Increase in serum creatinine (SCr) at 48-72 hours post dose

研究概览

简要总结

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Referred for contrast enhanced MDCT
  • Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
  • Diagnosed as having diabetes mellitus

排除标准

  • Unstable renal function
  • Unstable diabetes
  • Concurrent administration of nephrotoxic drugs
  • Undergoing dialysis

结局指标

主要结局

Increase in serum creatinine (SCr) at 48-72 hours post dose

次要结局

  • Decrease in estimated glomerular filtration rate (eGFR) at 48-72 hours post dose; occurrence of adverse events

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验